D. E. Shaw & Co. Inc. Has $39.75 Million Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

D. E. Shaw & Co. Inc. increased its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 48.7% during the second quarter, Holdings Channel reports. The institutional investor owned 580,359 shares of the biopharmaceutical company’s stock after purchasing an additional 190,080 shares during the period. D. E. Shaw & Co. Inc.’s holdings in Intra-Cellular Therapies were worth $39,749,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in ITCI. Avoro Capital Advisors LLC bought a new stake in shares of Intra-Cellular Therapies during the fourth quarter valued at approximately $161,543,000. Vanguard Group Inc. increased its stake in Intra-Cellular Therapies by 6.5% during the 4th quarter. Vanguard Group Inc. now owns 9,094,302 shares of the biopharmaceutical company’s stock valued at $651,334,000 after purchasing an additional 554,577 shares in the last quarter. Marshall Wace LLP acquired a new position in Intra-Cellular Therapies during the second quarter worth $34,178,000. Hood River Capital Management LLC bought a new position in shares of Intra-Cellular Therapies in the second quarter valued at $33,390,000. Finally, Point72 Asset Management L.P. grew its holdings in shares of Intra-Cellular Therapies by 218.9% during the second quarter. Point72 Asset Management L.P. now owns 554,186 shares of the biopharmaceutical company’s stock valued at $37,956,000 after buying an additional 380,420 shares during the last quarter. Institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of Intra-Cellular Therapies stock opened at $73.30 on Friday. The firm has a market cap of $7.74 billion, a PE ratio of -63.19 and a beta of 1.00. Intra-Cellular Therapies, Inc. has a 1 year low of $45.50 and a 1 year high of $84.89. The stock has a fifty day moving average price of $75.47 and a 200-day moving average price of $71.66.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. The business had revenue of $161.40 million during the quarter, compared to the consensus estimate of $157.74 million. Intra-Cellular Therapies had a negative net margin of 14.93% and a negative return on equity of 11.48%. The firm’s quarterly revenue was up 45.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.45) earnings per share. As a group, equities analysts anticipate that Intra-Cellular Therapies, Inc. will post -0.59 EPS for the current fiscal year.

Insider Transactions at Intra-Cellular Therapies

In related news, EVP Mark Neumann sold 18,714 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $75.08, for a total value of $1,405,047.12. Following the transaction, the executive vice president now owns 29,700 shares in the company, valued at $2,229,876. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO Sharon Mates sold 28,680 shares of Intra-Cellular Therapies stock in a transaction dated Friday, August 23rd. The shares were sold at an average price of $74.46, for a total value of $2,135,512.80. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares in the company, valued at $79,696,697.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mark Neumann sold 18,714 shares of the business’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the completion of the sale, the executive vice president now directly owns 29,700 shares in the company, valued at approximately $2,229,876. The disclosure for this sale can be found here. Insiders sold a total of 175,316 shares of company stock worth $13,037,345 in the last quarter. Insiders own 3.40% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on ITCI. Mizuho upped their target price on shares of Intra-Cellular Therapies from $96.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, June 21st. Piper Sandler upgraded Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and raised their target price for the company from $68.00 to $92.00 in a report on Friday, September 6th. Canaccord Genuity Group lifted their target price on Intra-Cellular Therapies from $107.00 to $113.00 and gave the company a “buy” rating in a research report on Thursday, June 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price target on shares of Intra-Cellular Therapies in a research report on Monday, September 16th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Intra-Cellular Therapies from $79.00 to $81.00 and gave the stock an “overweight” rating in a report on Wednesday, August 21st. Three research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $96.58.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.